Lates News

Merck (MRK.N) announced that its long-acting monoclonal antibody Clevrovimab injection (trade name: Anfuchang) has recently been approved by the China National Medical Products Administration for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born in the first RSV epidemic season.